ACS Medicinal Chemistry Letters
LETTER
’ REFERENCES
(20) Yang, H.; Liebeskind, L. S. A concise and scalable synthesis of
high enantiopurity (ꢀ)-D-erythro-sphingosine using peptidyl thiol ester-
boronic acid cross-coupling. Org. Lett. 2007, 9, 2993–2995.
(21) Liebeskind, L. S.; Yang, H. Synthesis of sphingosines and their
derivatives. PCT Int. Appl. (2008), WO CAN 148:331478 AN 2008:317747.
(22) On a large scale, thiol ester 1 was prepared in 99% yield and
99.6% ee, using reagent supported on resin. PS-Carbodiimide and PS-
thiophenol are both commercially available from Biotage.
(1) American Cancer Society (ACS). Cancer Facts and Figures,
2010 (Accessed July 2, 2010, at http://www.cancer.org/).
(2) Miyamoto, H.; Messing, E.; Chang, C. Androgen deprivation
therapy for prostate cancer: current status and future prospects. The
Prostate 2004, 9999:1, 1–22.
(3) Berthold, D. R.; Pond, G. R.; Soban, F.; de Wit, R.; Eisenberger,
M.; Tannock, I. F. Docetaxel plus prednisone or mitoxantrone plus
prednisone for advanced prostate cancer: updated survival in the TAX
27 study. J. Clin. Oncol. 2008, 26, 242–245.
(4) Liao, J.; Tao, J.; Lin, G.; Liu, D. Chemistry and biology of
sphingolipids. Tetrahedron 2005, 61, 4715–4733.
(5) Zheng, W.; Kollmeyer, J.; Symolon, H.; Momin, A.; Munter, E.;
Wang, E.; Kelly, S.; Allegood, J.; Liu, Y.; Peng, Q.; Ramaraju, H.; Sullards,
M.; Cabot, M.; Merrill, A. H., Jr. Ceramides and other bioactive
sphingolipid backbones in health and disease: Lipidomic analysis,
metabolism and roles in membrane structure, dynamics, signaling, and
autophagy. Biochim. Biophys. Acta 2006, 1758, 1864–1884.
(6) Morales, A.; Fernandez-Checa, J. Pharmacological modulation of
sphingolipids and role in disease and cancer cell biology. Mini-Rev. Med.
Chem. 2007, 7, 371–382.
(7) Nussbaumer, P. Medicinal chemistry aspects of drug targets in
sphingolipid metabolism. ChemMedChem 2008, 3, 543–551.
(8) For references that describe the link between S1P and cancer, see
refs 8ꢀ12:Payne, S. G.; Milstien, S.; Spiegel, S. Sphingosine-1-phos-
phate: dual messenger functions. FEBS Lett. 2002, 531, 54–57.
(9) Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: an enigmatic
signaling lipid. Nat. Rev. Mol. Cell Biol. 2003, 4, 397–407.
(10) Sabbadini, R. A. Targeting sphingosine-1-phosphate for cancer
therapy. Br. J. Cancer 2006, 95, 1131–1135.
(11) Pyne, N. J.; Pyne, S. Sphingosine-1-phosphate and cancer. Nat.
Rev. Cancer 2010, 10, 489–503.
(12) Leong, W. I.; Saba, J. D. S1P Metabolism in cancer and other
pathological conditions. Biochimie 2010, 92, 716–723.
(13) Merrill, A. H., Jr.; Nimkar, S.; Menaldino, D.; Hannun, Y. A.;
Loomis, C.; Bell, R. M.; Tyagi, S. R.; Lambeth, J. D.; Stevens, V. L.;
Hunter, R.; Liotta, D. C. Structural requirements for long chain
(sphingoid) base inhibition of protein kinase C in vitro and for the
cellular effects of these compounds. Biochemistry 1989, 28, 3138–
3145.
(14) Humph, H. U.; Schmelz, E. M.; Meredith, F. I. Acylation of
naturally occurring and synthetic 1-deoxysphinganines by ceramide
synthase. J. Biol. Chem. 1998, 273, 19060–19064.
(23) Liebeskind, L. S.; Srogl, J. Thiol ester-boronic acid coupling. A
mechanistically unprecedented and general ketone synthesis. J. Am.
Chem. Soc. 2000, 122, 11260–11261.
(24) Using THF, as previously described for the synthesis of Sphingo-
sine led to moderate yields and significant homocoupling product.
(25) Hoffmann, R. V.; Maslouh, N.; Cervantes-Lee, F. Highly
stereoselective syntheses of syn- and anti-1,2-amino alcohols. J. Org.
Chem. 2002, 67, 1045–1056.
(26) Shang, S.; Idaware, H.; Macks, D. E.; Ambrosini, L. M.; Tan,
D. S. A unified synthetic approach to polyketides having both skeletal
and stereochemical diversity. Org. Lett. 2007, 9, 1895–1898.
(27) Directed epoxidation using VO(acac)2/t-BuOOH, Shi epox-
idation/H2O2, or oxone reaction conditions led to either low reactivity
or moderate diastereoselectivity.
(28) Benedetti, F.; Berti, F.; Norbedo, S. Epoxyalcohol route to
hydroxyethylene dipeptide isosteres. Stereodivergent synthesis of the
diamino alcohol core of ritonavir and its C-2 epimer. J. Org. Chem. 2002,
67, 8635–8643.
(29) To confirm the absolute stereochemistry of the enigmol
diastereoisomers, compounds 3 were converted to their corresponding
oxazolidinones and analyzed by 1H NMR spectroscopy. Next, the
relative stereochemistry of the C3/C5 1,3-diol was confirmed using
Rychnovsky’s acetonide methodology with 13C NMR analysis. Final
compounds 5aꢀ5d were also compared with authentic samples, kindly
provided by Dr. Anatoliy Bushnev. See Supporting Information for more
details.
(15) Symolon, H.; Bushnev, A.; Peng, Q.; Ramaraju, H.; Mays, S. G.;
Allegood, J. C.; Pruett, S. T.; Sullards, M. C.; Dillehay, D. L.; Liotta,
D. C.; Merrill, A. H., Jr. Enigmol: A novel sphingolipid analog with anti-
cancer activity against cancer cell lines and in in vivo models for intestinal
and prostate cancer. Mol. Cancer Ther. 2010, in press.
(30) Liu, C.; Cripe, T. P.; Kim, M. O. Statistical Issues in Long-
itudinal Data Analysis for Treatment Efficacy Studies in the Biomedical
Sciences. Mol. Ther. 2010, 18, 1724–1730.
(31) Rayburn, E. R.; Wang, W.; Zhang, Z.; Li, M.; Zhang, R.; Wang,
H. Experimental therapy of prostate cancer with an immunomodulatory
oligonucleotide: effects on tumor growth, apoptosis, proliferation, and
potentiation of chemotherapy. Prostate 2006, 66, 1653–1663.
(32) In vivo data for the SRR diastereomer (5d) was not included
because of stability issues associated with this compound. Significant
decomposition was observed for this diastereomer when performing a
postassay LCMS analysis of the study samples. Further studies regarding
compound stability and in vivo efficacy are ongoing.
(33) Liu, L.; Coker, A. L.; Du, X. L.; Cormier, J. N.; Ford, C. E.; Fang,
S. Long-term survival after radical prostatectomy compared to other
treatments in older men with local/regional prostate cancer. J. Surg.
Oncol. 2008, 97, 583–591.
(16) Pruett, S. T. Biological mass spectrometry of sphingolipids in
drug discovery and development chemistry. Ph.D. Thesis, Emory
University, Atlanta, GA, 2006; p 169.
(17) Previously described syntheses of enigmol are described in refs
17ꢀ19:Bushnev, A. S.; Baillie, M. T.; Holt, J. J.; Menaldino, D. S.;
Merrill, A. H., Jr.; Liotta, D. C. An efficient asymmetric synthesis of
Enigmols (1-deoxy-5-hydroxysphingoid bases), an important class of
bioactive lipid modulators. ARKIVOC 2010, 8, 263–277.
(18) Wiseman, J. M.; McDonald, F. E.; Liotta, D. C. 1-Deoxy-5-
hydroxysphingolipids as new anticancer principles: an efficient proce-
dure for stereoselective syntheses of 2-amino-3,5-diols. Org. Lett. 2005,
7, 3155ꢀ3157 (Addition and correction: Wiseman, J. M.; McDonald, F.
E.; Liotta, D. C. Org. Lett. 2007, 9, 2959).
(34) Azaka, H.; Hinotsu, S.; Usami, M.; Arai, Y.; Kanetake, H.; Naito,
S.; Hirao, Y. Combined androgen blockade with bicalutamide for
advanced prostate cancer. Cancer 2009, 115, 3437–3445.
(35) Wright, J. L.; Higano, C. S.; Lin, D. W. Intermittent androgen
deprivation: Clinical experience and practical applications. Urol. Clin. N.
Am. 2006, 33, 167–179.
(19) Menaldino, D. S. Asymmetric Syntheses of Amino Alcohols as
Bioactive Compounds. Chapter One: Syntheses of Sphingolipid Ana-
logs as Inhibitors of the Protein Kinase C Enzyme System. Chapter Two:
Syntheses of Fumonisin Analogs as Non-Metabolizable Protein Kinase
C Inhibitors and as Proposed Ceramide Synthase Inhibitors. Ph.D.
Thesis, Emory University, Atlanta, GA, 1992.
443
dx.doi.org/10.1021/ml2000164 |ACS Med. Chem. Lett. 2011, 2, 438–443